Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Genomma Lab InternacionalB de CV's
Operating Income
for the
three
months ended in Mar. 2026 was MXN874 Mil. Genomma Lab InternacionalB de CV's Interest Expense for the
three
months ended in Mar. 2026 was MXN-178 Mil.
Genomma Lab InternacionalB de CV's interest coverage for the quarter that ended in Mar. 2026 was 4.92.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Genomma Lab InternacionalB de CV's Interest Coverage or its related term are showing as below:
MEX:LABB'
s Interest Coverage Range Over the Past 10 Years
Min: 0.58 Med: 4.56 Max: 6.74
Current: 4.91
MEX:LABB's Interest Coverage is ranked worse than 70.8% of 685
companies
in the Drug Manufacturers industry
Industry Median: 12.78
vs MEX:LABB: 4.91
Genomma Lab InternacionalB de CV (MEX:LABB) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Genomma Lab InternacionalB de CV Interest Coverage Related Terms
Genomma Lab InternacionalB de CV Interest Coverage Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Genomma Lab InternacionalB de CV Interest Coverage Chart
MEX:LABB vs ZTS, UTHR, VTRS: Interest Coverage Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Genomma Lab InternacionalB de CV's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genomma Lab InternacionalB de CV Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Genomma Lab InternacionalB de CV's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Genomma Lab InternacionalB de CV's Interest Coverage falls into.
Genomma Lab InternacionalB de CV Interest Coverage Calculation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genomma Lab InternacionalB de CV (MEX:LABB) has a Interest Coverage of 4.92 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Genomma Lab InternacionalB de CV and its competitors. This is near median its historical median of 4.56. Over the past decade, Genomma Lab InternacionalB de CV's Interest Coverage has ranged from 0.58 to 6.74. According to the industry distribution chart, Genomma Lab InternacionalB de CV ranks #485 out of 685 companies in the Drug Manufacturers industry, placing it in the top 70.8%.
Is Genomma Lab InternacionalB de CV's Interest Coverage too high?
Genomma Lab InternacionalB de CV's current Interest Coverage of 4.92 is near median its 10-year median of 4.56. Over the past 10 years, this metric has ranged from a low of 0.58 to a high of 6.74. The Drug Manufacturers industry median Interest Coverage is 12.78. Genomma Lab InternacionalB de CV's value of 4.92 is 61.5% below this industry median. Based on the distribution chart, Genomma Lab InternacionalB de CV ranks #485 out of 685 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Genomma Lab InternacionalB de CV has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genomma Lab InternacionalB de CV's Interest Coverage compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Genomma Lab InternacionalB de CV ranks #485 out of 685 companies for Interest Coverage. This places Genomma Lab InternacionalB de CV in the lower half of its industry. The industry median Interest Coverage is 12.78. Genomma Lab InternacionalB de CV's value of 4.92 is 61.5% below this benchmark. Historically, Genomma Lab InternacionalB de CV's own Interest Coverage has ranged from 0.58 to 6.74 over the past decade. While the company's 10-year median is 4.56 vs. the industry median of 12.78, Genomma Lab InternacionalB de CV has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.78, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genomma Lab InternacionalB de CV's current Interest Coverage of 4.92 is 61.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Genomma Lab InternacionalB de CV and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genomma Lab InternacionalB de CV's current Interest Coverage is 4.92, which is near median its own 10-year median of 4.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomma Lab InternacionalB de CV stock overvalued right now?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV (MEX:LABB) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN17.64, compared to a current price of MXN15.04 — trading 14.7% below its estimated fair value. The current Interest Coverage is 4.92, which is near median its 10-year median of 4.56 and 61.5% below the Drug Manufacturers industry median of 12.78. Genomma Lab InternacionalB de CV's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Genomma Lab InternacionalB de CV (MEX:LABB), the current Interest Coverage is 4.92 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genomma Lab InternacionalB de CV (MEX:LABB) Overvalued in 2026?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV stock appears to be undervalued.
The current stock price of MXN15.04 is trading 14.7% below its estimated GF Value™ of MXN17.64.
GuruFocus considers Genomma Lab InternacionalB de CV to be Modestly Undervalued.
Key valuation signals for MEX:LABB:
Interest Coverage: 4.92 (near median its 10-year median of 4.56)
GF Value™: MXN17.64 vs. price of MXN15.04 (14.7% below fair value)
Industry Position: 61.5% below the Drug Manufacturers median (#485 of 685)
No single metric tells the full story. See the MEX:LABB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genomma Lab InternacionalB de CV Business Description
Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
66GF Score
Get the complete analysis for MEX:LABB
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:LABB has been successfully added to your 
